News
-
New research comparing HIV medications set to change international recommendations
The WHO-funded study shows that dolutegravir is the optimal choice for first-line treatment of HIV
-
Examining the results of CTN 297: Black PRAISE
The Black PRAISE team have pioneered a novel intervention aimed at reducing HIV-related stigma while strengthening the HIV…
-
Engage-COVID-19
New funding for CTN 300-2 will allow the study team to document COVID-19 infection, immunity, and related determinants…
-
OPAL-COVID-19 Study
Dr. Bertrand Lebouché joins the creators of the health app Opal to repurpose it for COVID-19 patients recovering…
-
A collaborative approach to women-centred HIV care
The CTN 262 CHIWOS study have launched an all-encompassing Women-Centred HIV Care model and two toolkits
-
Here’s what we know about COVID-19 & HIV
Many questions remain about COVID-19 and what it means for people living with HIV. We explore the research…
-
Drug repurposing: could an HIV medication help in the fight against COVID-19?
Dr. Darrell Tan received funding for his study ‘COVID-19 ring-based prevention trial for undermining spread (CORPUS)’
-
The enigma of HIV’s effects on aging
People living with HIV present with age-related diseases sooner than the general population, but little is known as…
-
CHANGE HIV: A Healthy Aging Study
There is so much we do not know about HIV and aging, but the CHANGE HIV study (CTN…
